TrialNature communications2025

Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial.

Chee Khoon Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.